TARC/CCL17, Human (sf9)

• UNSPSC Description:

  TARC/CCL17 Protein, Human (sf9) is the first CC chemokine identified to interact with T cells with high affinity and bind to the CCR4 receptor to mediate inflammation, cancer, and autoimmune related diseases. TARC/CCL17 Protein, Human (sf9) is a recombinant human TARC/CCL17(M1-S94) protein expressed by Sf9 insect cells[1][2].

• Type:

  Recombinant Proteins

• Assay Protocol:

  https://www.medchemexpress.com/cytokines/tarc-ccl17-protein-human-sf9.html

• Purity:

  96.60

• Molecular Weight:

  Approximately 10 kDa

• References & Citations:

  [1]Julien Catherine, et al. What does elevated TARC/CCL17 expression tell us about eosinophilic disorders? Semin Immunopathol. 2021 Jun;43(3):439-458.|[2]Jan Korbecki, et al. CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of the Ligands of Receptors CCR1, CCR2, CCR3, and CCR4. Int J Mol Sci. 2020 Nov 9;21(21):8412.|[3]Yoshiki Mizukami, et al. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. Int J Cancer. 2008 May 15;122(10):2286-93.|[4]Amr A Al-haidari, et al. CCR4 mediates CCL17 (TARC)-induced migration of human colon cancer cells via RhoA/Rho-kinase signaling. Int J Colorectal Dis. 2013 Nov;28(11):1479-87.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  Stored at -20°C for 2 years